Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial

Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of e...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Stroke (1970) 2021-03, Vol.52 (3), p.772-780
Hauptverfasser: Xu, Jie, Wang, Anxin, Meng, Xia, Yalkun, Gulbahram, Xu, Anding, Gao, Zhiqiang, Chen, Huisheng, Ji, Yong, Xu, Jun, Geng, Deqin, Zhu, Runxiu, Liu, Bo, Dong, Aiqin, Mu, Hua, Lu, Zhihong, Li, Shuya, Zheng, Huaguang, Chen, Xia, Wang, Yilong, Zhao, Xingquan, Wang, Yongjun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 780
container_issue 3
container_start_page 772
container_title Stroke (1970)
container_volume 52
creator Xu, Jie
Wang, Anxin
Meng, Xia
Yalkun, Gulbahram
Xu, Anding
Gao, Zhiqiang
Chen, Huisheng
Ji, Yong
Xu, Jun
Geng, Deqin
Zhu, Runxiu
Liu, Bo
Dong, Aiqin
Mu, Hua
Lu, Zhihong
Li, Shuya
Zheng, Huaguang
Chen, Xia
Wang, Yilong
Zhao, Xingquan
Wang, Yongjun
description Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome in patients with acute ischemic stroke (AIS). Methods: A multicenter, randomized, double-blind, comparative, phase III clinical trial was conducted at 48 hospitals in China between May 2015 and December 2016. Inclusion criteria included patients diagnosed as AIS, 35 to 80 years of age, National Institutes of Health Stroke Scale Score between 4 and 24, and within 48 hours of AIS onset. AIS patients were randomized in 1:1 ratio into 2 treatment arms: 14-day infusion of edaravone dexborneol or edaravone injection. The primary end point was the proportion of patients with modified Rankin Scale score
doi_str_mv 10.1161/STROKEAHA.120.031197
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_33588596</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2490120877</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3522-eaf80169d838eb979788cbb060a667881ff5e10394dcd4012e2831ab9b5ae0273</originalsourceid><addsrcrecordid>eNqNUttu1DAQjRCILoU_QMiPSDSLL7nYvIV0oSsqFbULr5aTTJRQJ97aTpf2K_hknG7ZvvLimdGcM6M5x1H0luAlIRn5eLW5vPi2Ks6KJaF4iRkhIn8WLUhKkzjJKH8eLTBmIqaJEEfRK-d-YYwp4-nL6IixlPNUZIvoz6pRVt2aEdAp_K6MHcFo9BOsmxx66hV6fltjke8AbSwoP8DokWlRUU8e0NrVHQx9ja68NdfwCRXoe6dcaKzXJ-hSjY0Z-ntoTtCpmSoN8Wfdj6EqzbANS3x_O4_tlX4dvWiVdvDmMR5HP76sNuVZfH7xdV0W53HNUkpjUC3HJBMNZxwqkYuc87qqcIZVloWctG0KJNyfNHWTYEKBckZUJapUAaY5O47e7-durbmZwHk59K4GrVVQYHIyyBZYmOczNNlDa2ucs9DKre0HZe8kwXL2Qh68kIEi914E2rvHDVM1QHMg_RM_AD7sATuoTOvqHsYaDrDgVsYEI2keMjyP4_-PLnsfNDVjaabRPx2wM9oHa6_1tAMrO1Dad_KBkOU4ppgGxUIV44ev8he3Q7Wk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2490120877</pqid></control><display><type>article</type><title>Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial</title><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Journals@Ovid Complete</source><source>Web of Science - Science Citation Index Expanded - 2021&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><source>Alma/SFX Local Collection</source><creator>Xu, Jie ; Wang, Anxin ; Meng, Xia ; Yalkun, Gulbahram ; Xu, Anding ; Gao, Zhiqiang ; Chen, Huisheng ; Ji, Yong ; Xu, Jun ; Geng, Deqin ; Zhu, Runxiu ; Liu, Bo ; Dong, Aiqin ; Mu, Hua ; Lu, Zhihong ; Li, Shuya ; Zheng, Huaguang ; Chen, Xia ; Wang, Yilong ; Zhao, Xingquan ; Wang, Yongjun</creator><creatorcontrib>Xu, Jie ; Wang, Anxin ; Meng, Xia ; Yalkun, Gulbahram ; Xu, Anding ; Gao, Zhiqiang ; Chen, Huisheng ; Ji, Yong ; Xu, Jun ; Geng, Deqin ; Zhu, Runxiu ; Liu, Bo ; Dong, Aiqin ; Mu, Hua ; Lu, Zhihong ; Li, Shuya ; Zheng, Huaguang ; Chen, Xia ; Wang, Yilong ; Zhao, Xingquan ; Wang, Yongjun ; TASTE Trial Investigators</creatorcontrib><description>Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome in patients with acute ischemic stroke (AIS). Methods: A multicenter, randomized, double-blind, comparative, phase III clinical trial was conducted at 48 hospitals in China between May 2015 and December 2016. Inclusion criteria included patients diagnosed as AIS, 35 to 80 years of age, National Institutes of Health Stroke Scale Score between 4 and 24, and within 48 hours of AIS onset. AIS patients were randomized in 1:1 ratio into 2 treatment arms: 14-day infusion of edaravone dexborneol or edaravone injection. The primary end point was the proportion of patients with modified Rankin Scale score &lt;= 1 on day 90 after randomization. Results: One thousand one hundred sixty-five AIS patients were randomly allocated to the edaravone dexborneol group (n=585) or the edaravone group (n=580). The edaravone dexborneol group showed significantly higher proportion of patients experiencing good functional outcomes on day 90 after randomization, compared with the edaravone group (modified Rankin Scale score &lt;= 1, 67.18% versus 58.97%; odds ratio, 1.42 [95% CI, 1.12-1.81]; P=0.004). The prespecified subgroup analyses indicated that a greater benefit was observed in female patients than their male counterparts (2.26, 1.49-3.43 versus 1.14, 0.85-1.52). Conclusions: When edaravone dexborneol versus edaravone was administered within 48 hours after AIS, 90-day good functional outcomes favored the edaravone dexborneol group, especially in female patients. Registration: URL: . Unique identifier: NCT02430350.</description><identifier>ISSN: 0039-2499</identifier><identifier>EISSN: 1524-4628</identifier><identifier>DOI: 10.1161/STROKEAHA.120.031197</identifier><identifier>PMID: 33588596</identifier><language>eng</language><publisher>PHILADELPHIA: Lippincott Williams &amp; Wilkins</publisher><subject>Cardiovascular System &amp; Cardiology ; Clinical Neurology ; Life Sciences &amp; Biomedicine ; Neurosciences &amp; Neurology ; Peripheral Vascular Disease ; Science &amp; Technology</subject><ispartof>Stroke (1970), 2021-03, Vol.52 (3), p.772-780</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>108</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000639315700007</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c3522-eaf80169d838eb979788cbb060a667881ff5e10394dcd4012e2831ab9b5ae0273</citedby><cites>FETCH-LOGICAL-c3522-eaf80169d838eb979788cbb060a667881ff5e10394dcd4012e2831ab9b5ae0273</cites><orcidid>0000-0002-7486-1992 ; 0000-0003-4351-2877 ; 0000-0003-3154-0985 ; 0000-0002-8034-9477 ; 0000-0003-2725-2788 ; 0000-0001-8345-5147 ; 0000-0002-9976-2341 ; 0000-0002-7263-0365</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,3689,27931,27932,39265</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33588596$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Xu, Jie</creatorcontrib><creatorcontrib>Wang, Anxin</creatorcontrib><creatorcontrib>Meng, Xia</creatorcontrib><creatorcontrib>Yalkun, Gulbahram</creatorcontrib><creatorcontrib>Xu, Anding</creatorcontrib><creatorcontrib>Gao, Zhiqiang</creatorcontrib><creatorcontrib>Chen, Huisheng</creatorcontrib><creatorcontrib>Ji, Yong</creatorcontrib><creatorcontrib>Xu, Jun</creatorcontrib><creatorcontrib>Geng, Deqin</creatorcontrib><creatorcontrib>Zhu, Runxiu</creatorcontrib><creatorcontrib>Liu, Bo</creatorcontrib><creatorcontrib>Dong, Aiqin</creatorcontrib><creatorcontrib>Mu, Hua</creatorcontrib><creatorcontrib>Lu, Zhihong</creatorcontrib><creatorcontrib>Li, Shuya</creatorcontrib><creatorcontrib>Zheng, Huaguang</creatorcontrib><creatorcontrib>Chen, Xia</creatorcontrib><creatorcontrib>Wang, Yilong</creatorcontrib><creatorcontrib>Zhao, Xingquan</creatorcontrib><creatorcontrib>Wang, Yongjun</creatorcontrib><creatorcontrib>TASTE Trial Investigators</creatorcontrib><title>Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial</title><title>Stroke (1970)</title><addtitle>STROKE</addtitle><addtitle>Stroke</addtitle><description>Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome in patients with acute ischemic stroke (AIS). Methods: A multicenter, randomized, double-blind, comparative, phase III clinical trial was conducted at 48 hospitals in China between May 2015 and December 2016. Inclusion criteria included patients diagnosed as AIS, 35 to 80 years of age, National Institutes of Health Stroke Scale Score between 4 and 24, and within 48 hours of AIS onset. AIS patients were randomized in 1:1 ratio into 2 treatment arms: 14-day infusion of edaravone dexborneol or edaravone injection. The primary end point was the proportion of patients with modified Rankin Scale score &lt;= 1 on day 90 after randomization. Results: One thousand one hundred sixty-five AIS patients were randomly allocated to the edaravone dexborneol group (n=585) or the edaravone group (n=580). The edaravone dexborneol group showed significantly higher proportion of patients experiencing good functional outcomes on day 90 after randomization, compared with the edaravone group (modified Rankin Scale score &lt;= 1, 67.18% versus 58.97%; odds ratio, 1.42 [95% CI, 1.12-1.81]; P=0.004). The prespecified subgroup analyses indicated that a greater benefit was observed in female patients than their male counterparts (2.26, 1.49-3.43 versus 1.14, 0.85-1.52). Conclusions: When edaravone dexborneol versus edaravone was administered within 48 hours after AIS, 90-day good functional outcomes favored the edaravone dexborneol group, especially in female patients. Registration: URL: . Unique identifier: NCT02430350.</description><subject>Cardiovascular System &amp; Cardiology</subject><subject>Clinical Neurology</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>Neurosciences &amp; Neurology</subject><subject>Peripheral Vascular Disease</subject><subject>Science &amp; Technology</subject><issn>0039-2499</issn><issn>1524-4628</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><recordid>eNqNUttu1DAQjRCILoU_QMiPSDSLL7nYvIV0oSsqFbULr5aTTJRQJ97aTpf2K_hknG7ZvvLimdGcM6M5x1H0luAlIRn5eLW5vPi2Ks6KJaF4iRkhIn8WLUhKkzjJKH8eLTBmIqaJEEfRK-d-YYwp4-nL6IixlPNUZIvoz6pRVt2aEdAp_K6MHcFo9BOsmxx66hV6fltjke8AbSwoP8DokWlRUU8e0NrVHQx9ja68NdfwCRXoe6dcaKzXJ-hSjY0Z-ntoTtCpmSoN8Wfdj6EqzbANS3x_O4_tlX4dvWiVdvDmMR5HP76sNuVZfH7xdV0W53HNUkpjUC3HJBMNZxwqkYuc87qqcIZVloWctG0KJNyfNHWTYEKBckZUJapUAaY5O47e7-durbmZwHk59K4GrVVQYHIyyBZYmOczNNlDa2ucs9DKre0HZe8kwXL2Qh68kIEi914E2rvHDVM1QHMg_RM_AD7sATuoTOvqHsYaDrDgVsYEI2keMjyP4_-PLnsfNDVjaabRPx2wM9oHa6_1tAMrO1Dad_KBkOU4ppgGxUIV44ev8he3Q7Wk</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Xu, Jie</creator><creator>Wang, Anxin</creator><creator>Meng, Xia</creator><creator>Yalkun, Gulbahram</creator><creator>Xu, Anding</creator><creator>Gao, Zhiqiang</creator><creator>Chen, Huisheng</creator><creator>Ji, Yong</creator><creator>Xu, Jun</creator><creator>Geng, Deqin</creator><creator>Zhu, Runxiu</creator><creator>Liu, Bo</creator><creator>Dong, Aiqin</creator><creator>Mu, Hua</creator><creator>Lu, Zhihong</creator><creator>Li, Shuya</creator><creator>Zheng, Huaguang</creator><creator>Chen, Xia</creator><creator>Wang, Yilong</creator><creator>Zhao, Xingquan</creator><creator>Wang, Yongjun</creator><general>Lippincott Williams &amp; Wilkins</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-7486-1992</orcidid><orcidid>https://orcid.org/0000-0003-4351-2877</orcidid><orcidid>https://orcid.org/0000-0003-3154-0985</orcidid><orcidid>https://orcid.org/0000-0002-8034-9477</orcidid><orcidid>https://orcid.org/0000-0003-2725-2788</orcidid><orcidid>https://orcid.org/0000-0001-8345-5147</orcidid><orcidid>https://orcid.org/0000-0002-9976-2341</orcidid><orcidid>https://orcid.org/0000-0002-7263-0365</orcidid></search><sort><creationdate>20210301</creationdate><title>Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial</title><author>Xu, Jie ; Wang, Anxin ; Meng, Xia ; Yalkun, Gulbahram ; Xu, Anding ; Gao, Zhiqiang ; Chen, Huisheng ; Ji, Yong ; Xu, Jun ; Geng, Deqin ; Zhu, Runxiu ; Liu, Bo ; Dong, Aiqin ; Mu, Hua ; Lu, Zhihong ; Li, Shuya ; Zheng, Huaguang ; Chen, Xia ; Wang, Yilong ; Zhao, Xingquan ; Wang, Yongjun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3522-eaf80169d838eb979788cbb060a667881ff5e10394dcd4012e2831ab9b5ae0273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cardiovascular System &amp; Cardiology</topic><topic>Clinical Neurology</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>Neurosciences &amp; Neurology</topic><topic>Peripheral Vascular Disease</topic><topic>Science &amp; Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Xu, Jie</creatorcontrib><creatorcontrib>Wang, Anxin</creatorcontrib><creatorcontrib>Meng, Xia</creatorcontrib><creatorcontrib>Yalkun, Gulbahram</creatorcontrib><creatorcontrib>Xu, Anding</creatorcontrib><creatorcontrib>Gao, Zhiqiang</creatorcontrib><creatorcontrib>Chen, Huisheng</creatorcontrib><creatorcontrib>Ji, Yong</creatorcontrib><creatorcontrib>Xu, Jun</creatorcontrib><creatorcontrib>Geng, Deqin</creatorcontrib><creatorcontrib>Zhu, Runxiu</creatorcontrib><creatorcontrib>Liu, Bo</creatorcontrib><creatorcontrib>Dong, Aiqin</creatorcontrib><creatorcontrib>Mu, Hua</creatorcontrib><creatorcontrib>Lu, Zhihong</creatorcontrib><creatorcontrib>Li, Shuya</creatorcontrib><creatorcontrib>Zheng, Huaguang</creatorcontrib><creatorcontrib>Chen, Xia</creatorcontrib><creatorcontrib>Wang, Yilong</creatorcontrib><creatorcontrib>Zhao, Xingquan</creatorcontrib><creatorcontrib>Wang, Yongjun</creatorcontrib><creatorcontrib>TASTE Trial Investigators</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Stroke (1970)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Xu, Jie</au><au>Wang, Anxin</au><au>Meng, Xia</au><au>Yalkun, Gulbahram</au><au>Xu, Anding</au><au>Gao, Zhiqiang</au><au>Chen, Huisheng</au><au>Ji, Yong</au><au>Xu, Jun</au><au>Geng, Deqin</au><au>Zhu, Runxiu</au><au>Liu, Bo</au><au>Dong, Aiqin</au><au>Mu, Hua</au><au>Lu, Zhihong</au><au>Li, Shuya</au><au>Zheng, Huaguang</au><au>Chen, Xia</au><au>Wang, Yilong</au><au>Zhao, Xingquan</au><au>Wang, Yongjun</au><aucorp>TASTE Trial Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial</atitle><jtitle>Stroke (1970)</jtitle><stitle>STROKE</stitle><addtitle>Stroke</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>52</volume><issue>3</issue><spage>772</spage><epage>780</epage><pages>772-780</pages><issn>0039-2499</issn><eissn>1524-4628</eissn><abstract>Background and Purpose: Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The present clinical trial aimed at testing the effects of edaravone dexborneol versus edaravone on 90-day functional outcome in patients with acute ischemic stroke (AIS). Methods: A multicenter, randomized, double-blind, comparative, phase III clinical trial was conducted at 48 hospitals in China between May 2015 and December 2016. Inclusion criteria included patients diagnosed as AIS, 35 to 80 years of age, National Institutes of Health Stroke Scale Score between 4 and 24, and within 48 hours of AIS onset. AIS patients were randomized in 1:1 ratio into 2 treatment arms: 14-day infusion of edaravone dexborneol or edaravone injection. The primary end point was the proportion of patients with modified Rankin Scale score &lt;= 1 on day 90 after randomization. Results: One thousand one hundred sixty-five AIS patients were randomly allocated to the edaravone dexborneol group (n=585) or the edaravone group (n=580). The edaravone dexborneol group showed significantly higher proportion of patients experiencing good functional outcomes on day 90 after randomization, compared with the edaravone group (modified Rankin Scale score &lt;= 1, 67.18% versus 58.97%; odds ratio, 1.42 [95% CI, 1.12-1.81]; P=0.004). The prespecified subgroup analyses indicated that a greater benefit was observed in female patients than their male counterparts (2.26, 1.49-3.43 versus 1.14, 0.85-1.52). Conclusions: When edaravone dexborneol versus edaravone was administered within 48 hours after AIS, 90-day good functional outcomes favored the edaravone dexborneol group, especially in female patients. Registration: URL: . Unique identifier: NCT02430350.</abstract><cop>PHILADELPHIA</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>33588596</pmid><doi>10.1161/STROKEAHA.120.031197</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-7486-1992</orcidid><orcidid>https://orcid.org/0000-0003-4351-2877</orcidid><orcidid>https://orcid.org/0000-0003-3154-0985</orcidid><orcidid>https://orcid.org/0000-0002-8034-9477</orcidid><orcidid>https://orcid.org/0000-0003-2725-2788</orcidid><orcidid>https://orcid.org/0000-0001-8345-5147</orcidid><orcidid>https://orcid.org/0000-0002-9976-2341</orcidid><orcidid>https://orcid.org/0000-0002-7263-0365</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0039-2499
ispartof Stroke (1970), 2021-03, Vol.52 (3), p.772-780
issn 0039-2499
1524-4628
language eng
recordid cdi_pubmed_primary_33588596
source American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Journals@Ovid Complete; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Alma/SFX Local Collection
subjects Cardiovascular System & Cardiology
Clinical Neurology
Life Sciences & Biomedicine
Neurosciences & Neurology
Peripheral Vascular Disease
Science & Technology
title Edaravone Dexborneol Versus Edaravone Alone for the Treatment of Acute Ischemic Stroke: A Phase III, Randomized, Double-Blind, Comparative Trial
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T18%3A58%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Edaravone%20Dexborneol%20Versus%20Edaravone%20Alone%20for%20the%20Treatment%20of%20Acute%20Ischemic%20Stroke:%20A%20Phase%20III,%20Randomized,%20Double-Blind,%20Comparative%20Trial&rft.jtitle=Stroke%20(1970)&rft.au=Xu,%20Jie&rft.aucorp=TASTE%20Trial%20Investigators&rft.date=2021-03-01&rft.volume=52&rft.issue=3&rft.spage=772&rft.epage=780&rft.pages=772-780&rft.issn=0039-2499&rft.eissn=1524-4628&rft_id=info:doi/10.1161/STROKEAHA.120.031197&rft_dat=%3Cproquest_pubme%3E2490120877%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2490120877&rft_id=info:pmid/33588596&rfr_iscdi=true